Submit Manuscript  

Article Details


Anti-fibrotic drugs for Crohn’s disease: Ready for prime time?

Author(s):

Marjorie Argollo, Daniela Gilardi, Giulia Roda, Gionata Fiorino, Laurent Peyrin-Biroulet and Silvio Danese*  

Abstract:


Intestinal fibrosis, driven by chronic inflammation in Crohn’s disease, can be defined as an excessive accumulation of extracellular matrix in the affected gut segment ultimately leading to an impaired wound healing and cumulative tissue damage, possibly resulting in organ dysfunction, formation of stenotic lesions and necessity of surgical intervention. Despite continuous advances in developing novel treatment modalities targeting different pathways to control chronic gut inflammation in CD, no effective anti-fibrotic agents have been released, to date. Thus, a better understanding on the molecular and cellular mechanisms underlying intestinal fibrosis, is key to move this area of investigation forward.

Keywords:

anti-fibrotic drugs, Crohn’s disease, intestinal fibrosis, treatment

Affiliation:

IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan



Full Text Inquiry